BioReference Laboratories

122 articles with BioReference Laboratories

• Saol Therapeutics and GeneDx, Inc. Collaborate to Detect Patients with Rare Mitochondrial Disease

  3/1/2022

  Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc. a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, to assist in identifying patients diagnosed with a rare mitochondrial disease, Pyruvate Dehydrogenase Complex Deficiency who may be eligible to participate in a Phase 3 clinical trial.

• BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.

  11/29/2021

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), announced COVID-19 testing preparedness for the Omicron Variant.

• GeneDx Announces the Sequencing of More Than 300,000 Clinical Patient Exomes

  9/21/2021

  GeneDx, Inc., a leader in genomic analysis, a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced it has completed clinical genetic exome sequencing for more than 300,000 patients, making the company's dataset the largest of its kind in the world.

• BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business

  8/16/2021

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced the acquisition of the U.S. Ariosa centralized laboratory prenatal testing business from Roche.

• BioReference Laboratories Announces First COVID-19 Testing Program for Cruise Industry

  6/22/2021

  BioReference Laboratories, Inc. today announced a COVID-19 testing program for U.S. based crew and guests who cruise with Royal Caribbean Group, helping provide a safe environment for travelers.

• Major League Soccer Renews with BioReference Laboratories as COVID-19 Testing Provider for Second Year

  4/27/2021

  BioReference Laboratories, Inc., an OPKO Health company, announced its renewal as the COVID-19 testing provider for Major League Soccer, which began on April 17 along with the 2021 MLS season.

• BioReference Laboratories Expands Its Major League Sports Relationships with Addition of Major League Baseball

  4/1/2021

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced a COVID-19 testing agreement for players and staff, stadium employees and league staff for the 2021 Major League Baseball (MLB) season.  

• Gestalt Diagnostics' PathFlow Selected by BioReference Laboratories for Pathology Laboratory Business

  3/30/2021

  Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution, PathFlow®, to support its pathology business.

• BioReference Laboratories Expands COVID-19 School Testing Program

  3/26/2021

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the expansion of its COVID-19 school testing program to support the return to in-person classroom instruction across the country.

• New York State Partners with BioReference Laboratories to Spearhead the NY Forward COVID-19 Rapid Test Program to Help Reopen the New York Economy

  2/22/2021

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced its participation in the NY Forward Rapid Testing Program and opened eight locations offering COVID-19 rapid testing around New York

• OPKO Health's BioReference Laboratories Team-up with the National Basketball Association and National Hockey League to Provide Players and Staff with COVID-19 Testing

  1/26/2021

  BioReference executes COVID-19 testing program for NBA and NHL for 2020-21 seasons, as well as U.S. Women's and Men's National Soccer Teams, Winter X Games and NBA G League

• OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access

  1/13/2021

  Scarlet brings diagnostic service to patients' homes, offices and other preferred locations, delivering an on-demand, safe and convenient diagnostic experience for patients and healthcare providers

• OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

  1/4/2021

  Nearly 210,000 New York City students, teachers, principals and staff were tested by BioReference with a positivity rate of 0.47%

• Buffalo Bills and OPKO Health's BioReference Laboratories Initiate the First Large Scale, Mandatory COVID-19 Fan Testing Program

  12/31/2020

  Buffalo Bills, 2020 AFC East Division Champions, and BioReference Laboratories, Inc., an OPKO Health company, announced they will be performing fan testing for the AFC Divisional Wild Card playoff game at Bills Stadium in Orchard Park.

• OPKO Health's BioReference Laboratories Launches Multiplex COVID-19 and Influenza A/B Test

  10/20/2020

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), is now accepting specimens for a new multiplex COVID-19 and influenza test for use by healthcare providers, clinics and health systems throughout the United States, to aid in the diagnosis of COVID-19 and Influenza A or B (flu).

• OPKO Health's BioReference Laboratories Launches COVID-19 Testing Program for New York City Schools

  10/9/2020

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ :OPK), today announced the beginning of its COVID-19 testing program for New York City schools throughout the 2020-2021 school year to help ensure a safer school environment.

• OPKO Health's BioReference Laboratories Announces New York City Schools COVID-19 Testing Program

  9/2/2020

  The COVID-19 testing program will test principals, teachers and staff in preparation for a safer back-to-school environment

• OPKO Health's BioReference Laboratories Launches Best-in-Class Next-Generation Sequencing (NGS) Assay

  9/1/2020

  BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), along with its specialty oncology division, GenPath, today announced the launch of OnkoSight AdvancedTM, a next-generation sequencing (NGS) assay that enables revolutionary deoxyribonucleic acid (DNA) mutational profiling of tumor samples.

• OPKO Health's GeneDx Adds GenomeXpress to Its Industry-Leading Clinical Genomics Portfolio

  8/6/2020

  GeneDx, Inc., a subsidiary of BioReference Laboratories, Inc., an OPKO Health company, announced the launch of GenomeXpress, a rapid genome sequencing test.

• Geoff Monk, President of OPKO Health's BioReference Laboratories, Named to CEO Today's Healthcare 2020 Awards List

  7/21/2020

  BioReference Laboratories, Inc., an OPKO Health company, announced that Geoff Monk, President of BioReference Laboratories, was recognized by CEO Today Magazine as one of this year's 20 Healthcare Award winners.